Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.
News Feed
3 results loaded, newest first. End of these results. The latest changes are still being indexed. Try again shortly for updated results.
Tenax Therapeutics pauses LEVEL-2 enrollment
The company temporarily paused enrollment to amend inclusion criteria and seek FDA Type C feedback after Phase 3 analyses showed benefit in sicker PH-HFpEF patients.
TENX As previously announced, Tenax Therapeutics, Inc. (the "Company") is enriching its LEVEL-2 clinical trial based on key learnings from i
TENX As previously announced, Tenax Therapeutics, Inc. (the "Company") is enriching its LEVEL-2 clinical trial based on key learnings from its recently completed Phase 3 LEVEL trial of TNX-103 in PH-HFpEF. The Company intends to amend LEVEL-2 enrollment criteria, as set forth in the attached Investor Presentation. To m